Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.lungcan.2016.07.006 http://scihub22266oqcxt.onion/10.1016/j.lungcan.2016.07.006 C5003323!5003323!27565929     free     free     free Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Lung+Cancer 2016 ; 99 (ä): 137-42 Nephropedia Template TP {{tp|p=27565929|t=2016. The Effect of Statins on Survival in Patients with Stage IV Lung Cancer |pdf=|usr=}}{{27565929}} gab.com Text The Effect of Statins on Survival in Patients with Stage IV Lung Cancer JO: Lung Cancer http://www.kidney.de/pget.php?&tw=1&pmid=27565929 #FOAvip Objectives: Prior studies have shown an anticancer effect of statins in patients with certain malignancies. However, it is unclear whether statins have a mortality benefit in lung cancer. We compared survival of patients with stage IV non-small cell lung cancer (NSCLC) receiving vs. not receiving statins prior to diagnosis. Methods: Using data from the Surveillance, Epidemiology and End Results registry linked to Medicare claims, we identified 5,118 patients >65 years of age diagnosed with stage IV NSCLC between 2007 and 2009. We used propensity score methods to assess the association of statin use with overall and lung cancer-specific survival while controlling for measured confounders. Results: Overall, 27% of patients were on statins at time of lung cancer diagnosis. Median survival in the statin group was 7 months, compared to 4 months in patients not treated with statins (p<0.001). Propensity score analyses found that statin use was associated with improvement in overall (hazard ratio [HR]: 0.76, 95% confidence interval [CI]: 0.73?0.79) and lung cancer-specific survival (HR: 0.77, 95% CI: 0.73?0.81), after controlling for baseline patient characteristics, cancer characteristics, staging work-up and chemotherapy use. Conclusions: Statin use is associated with improved survival among patients with stage IV NSCLC suggesting a potential anticancer effect. Further research should evaluate plausible biological mechanisms as well as test the effect of statins in prospective clinical trials. Twit Text FOAVip The Effect of Statins on Survival in Patients with Stage IV Lung Cancer ????Lung Cancer http://www.kidney.de/pget.php?&tw=1&pmid=27565929 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=27565929 #FOAvip English Wikipedia <ref>{{Cite pmid|27565929}}</ref> The Effect of Statins on Survival in Patients with Stage IV Lung Cancer #MMPMID27565929 Lin JJ; Ezer N; Sigel K; Mhango G; Wisnivesky JP Lung Cancer 2016[Sep]; 99 (ä): 137-42 PMID27565929show ga Objectives: Prior studies have shown an anticancer effect of statins in patients with certain malignancies. However, it is unclear whether statins have a mortality benefit in lung cancer. We compared survival of patients with stage IV non-small cell lung cancer (NSCLC) receiving vs. not receiving statins prior to diagnosis. Methods: Using data from the Surveillance, Epidemiology and End Results registry linked to Medicare claims, we identified 5,118 patients >65 years of age diagnosed with stage IV NSCLC between 2007 and 2009. We used propensity score methods to assess the association of statin use with overall and lung cancer-specific survival while controlling for measured confounders. Results: Overall, 27% of patients were on statins at time of lung cancer diagnosis. Median survival in the statin group was 7 months, compared to 4 months in patients not treated with statins (p<0.001). Propensity score analyses found that statin use was associated with improvement in overall (hazard ratio [HR]: 0.76, 95% confidence interval [CI]: 0.73?0.79) and lung cancer-specific survival (HR: 0.77, 95% CI: 0.73?0.81), after controlling for baseline patient characteristics, cancer characteristics, staging work-up and chemotherapy use. Conclusions: Statin use is associated with improved survival among patients with stage IV NSCLC suggesting a potential anticancer effect. Further research should evaluate plausible biological mechanisms as well as test the effect of statins in prospective clinical trials. äThe Effect of Statins on Survival in Patients with Stage IV Lung Cance(epmc).pdf DeepDyve Pubget Overpricing